BCI Growth Neeuro is actively expanding with the launch of NeeuroOS Agent Studio and a strategic push into AI-integrated brain-computer interface development platforms, signaling a scalable opportunity to offer enterprise-grade digital therapeutics, research collaborations, and clinician-facing tools.

Clinical Validation The company emphasizes clinically validated research in partnership with A*STAR and collaborations with Duke-NUS and IMH, presenting a compelling value proposition for healthcare providers seeking evidence-based neurotherapy solutions and efficacy data to support procurement.

Therapeutic Portfolio NeeuroCogo and related digital therapeutic solutions powered by BCI target attention training and cognitive rehabilitation, creating cross-sell potential to hospitals, clinics, schools, and senior care facilities looking for scalable non-pharmacological interventions.

Global Reach With a global footprint and strategic partnerships, Neeuro can address multi-market needs and offer localized deployments, integration with existing health IT systems, and channel opportunities through distributors and academic partners.

Low Revenue, High Upsell Current revenue is under $1M, indicating a growth phase with significant upsell potential through platform monetization, licensing of NeeuroOS, professional services, training, and expansion of clinician analytics and AI-driven insights.